PT3713928T - Antagonistas de recetor b2 de bradicinina inovadores - Google Patents

Antagonistas de recetor b2 de bradicinina inovadores

Info

Publication number
PT3713928T
PT3713928T PT188189922T PT18818992T PT3713928T PT 3713928 T PT3713928 T PT 3713928T PT 188189922 T PT188189922 T PT 188189922T PT 18818992 T PT18818992 T PT 18818992T PT 3713928 T PT3713928 T PT 3713928T
Authority
PT
Portugal
Prior art keywords
receptor antagonists
novel bradykinin
bradykinin
novel
antagonists
Prior art date
Application number
PT188189922T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Pharvaris Netherlands B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharvaris Netherlands B V filed Critical Pharvaris Netherlands B V
Publication of PT3713928T publication Critical patent/PT3713928T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PT188189922T 2017-11-24 2018-11-23 Antagonistas de recetor b2 de bradicinina inovadores PT3713928T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP17203675 2017-11-24

Publications (1)

Publication Number Publication Date
PT3713928T true PT3713928T (pt) 2022-03-08

Family

ID=60473364

Family Applications (1)

Application Number Title Priority Date Filing Date
PT188189922T PT3713928T (pt) 2017-11-24 2018-11-23 Antagonistas de recetor b2 de bradicinina inovadores

Country Status (29)

Country Link
US (3) US10836748B2 (enExample)
EP (2) EP3713928B1 (enExample)
JP (2) JP7164619B2 (enExample)
KR (1) KR102413321B1 (enExample)
CN (1) CN111433196B (enExample)
AR (1) AR113839A1 (enExample)
AU (1) AU2018371186B2 (enExample)
BR (1) BR112020010298A2 (enExample)
CA (1) CA3082948A1 (enExample)
CY (1) CY1125348T1 (enExample)
DK (1) DK3713928T3 (enExample)
EA (1) EA202091256A1 (enExample)
ES (1) ES2908409T3 (enExample)
HR (1) HRP20220429T1 (enExample)
HU (1) HUE058217T2 (enExample)
IL (1) IL274883B2 (enExample)
LT (1) LT3713928T (enExample)
MA (1) MA50804B1 (enExample)
MX (1) MX2020005287A (enExample)
PH (1) PH12020550683A1 (enExample)
PL (1) PL3713928T3 (enExample)
PT (1) PT3713928T (enExample)
RS (1) RS63087B1 (enExample)
SG (1) SG11202004653TA (enExample)
SI (1) SI3713928T1 (enExample)
SM (1) SMT202200154T1 (enExample)
TW (1) TWI768156B (enExample)
UY (1) UY37981A (enExample)
WO (1) WO2019101906A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3713928B1 (en) 2017-11-24 2022-01-12 Pharvaris Netherlands B.V. Novel bradykinin b2 receptor antagonists
UY38706A (es) * 2019-05-23 2020-12-31 Pharvaris Gmbh Antagonistas cíclicos del receptor b2 de bradiquinina
AR118983A1 (es) * 2019-05-23 2021-11-17 Pharvaris Gmbh Antagonistas cíclicos del receptor b2 de bradiquinina
MX2023005563A (es) * 2020-11-12 2023-09-11 Pharvaris Gmbh Profilaxis y tratamiento del angioedema.
US20250145584A1 (en) 2021-08-05 2025-05-08 Pharvaris Gmbh Solid form of a bradykinin b2-receptor antagonist
HRP20240525T1 (hr) * 2021-08-05 2024-07-05 Pharvaris Gmbh Pripravak na bazi lipida za oralnu primjenu antagonista bradikininskog b2-receptora
US20250228781A1 (en) 2022-03-25 2025-07-17 Pharvaris Gmbh Solid composition comprising solubilised bradykinin b2-receptor antagonists
WO2023180577A1 (en) 2022-03-25 2023-09-28 Pharvaris Gmbh Therapeutic uses of bradykinin b2-receptor antagonists
TW202345810A (zh) 2022-03-25 2023-12-01 瑞士商帕法瑞斯有限責任公司 包含緩激肽b2受體拮抗劑之固態延長釋放組成物

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU680870B2 (en) 1993-04-28 1997-08-14 Astellas Pharma Inc. New heterocyclic compounds
EP0807105B1 (en) 1994-10-27 2004-06-16 Fujisawa Pharmaceutical Co., Ltd. Pyridopyrimidones, quinolines and fused n-heretocycles as bradykinin antagonists
FR2737892B1 (fr) 1995-08-17 1997-10-24 Fournier Ind & Sante Nouveaux composes de benzenesulfonamide, procede de preparation et utilisation en therapeutique
GB9602029D0 (en) 1996-02-01 1996-04-03 Fujisawa Pharmaceutical Co New heterocyclic compounds
DE19609827A1 (de) 1996-03-13 1997-09-18 Hoechst Ag Aminoalkyl- und Acylaminoalkylether, Verfahren zu deren Herstellung und ihre Verwendung als Bradykinin-Rezeptorantagonisten
DE19610784A1 (de) 1996-03-19 1997-09-25 Hoechst Ag Fluoralkyl- und Fluoralkoxysubstituierte heterocyclische Bradykinin-Antagonisten, Verfahren zu ihrer Herstellung und ihre Verwendung
DE19612067A1 (de) 1996-03-27 1997-10-02 Hoechst Ag Verwendung von Bradykinin-Antagonisten zur Herstellung von Arzneimitteln zur Behandlung von chronisch fibrogenetischen Lebererkrankungen und akuten Lebererkrankungen
AUPN952696A0 (en) 1996-04-29 1996-05-23 Fujisawa Pharmaceutical Co., Ltd. New heterocyclic compounds
DE19712960A1 (de) 1997-03-27 1998-10-01 Hoechst Ag Benzyloxy-substituierte, anellierte N-Heterocyclen, Verfahren zu ihrer Herstellung und ihre Verwendung als Bradykininrezeptorantagonisten
EP1085895A1 (en) 1998-06-08 2001-03-28 Advanced Medicine, Inc. Bradykinin antagonists
KR100419404B1 (ko) 1998-10-21 2004-02-21 후지사와 야꾸힝 고교 가부시키가이샤 공지된 브라디키닌 길항제의 유리질 형태
FR2790260B1 (fr) 1999-02-26 2001-05-04 Fournier Ind & Sante Nouveaux composes de n-(benzenesulfonamide), procede de preparation et utilisation en therapeutique
GB9913079D0 (en) 1999-06-04 1999-08-04 Novartis Ag Organic compounds
WO2001056995A1 (en) 2000-01-18 2001-08-09 Nuerogen Corporation Substituted imidazoles as selective modulators of bradykinin b2 receptors
CA2364178C (en) 2000-12-05 2006-01-10 Yasuhiro Katsu N-benzenesulfonyl l-proline compounds as bradykinin antagonists
AU2003226188A1 (en) 2002-04-10 2003-10-27 Ortho-Mcneil Pharmaceutical, Inc. Novel heteroaryl alkylamide derivatives useful as bradykinin receptor modulators
ITMI20021247A1 (it) 2002-06-07 2003-12-09 Menarini Ricerche Spa Antagonisti basici non peptidici della bradichinina e loro impiego informulazioni farmaceutiche
ITMI20041963A1 (it) 2004-10-15 2005-01-15 Luso Farmaco Inst "antagonisti non-peptidici della bradichinina e loro composizioni farmaceutiche"
EP1741444A1 (en) 2005-07-05 2007-01-10 Jerini AG Kinin antagonists for treating bladder dysfunction
TWI407960B (zh) * 2007-03-23 2013-09-11 Jerini Ag 小分子緩激肽b2受體調節劑
AR073304A1 (es) * 2008-09-22 2010-10-28 Jerini Ag Moduladores del receptor de bradiquinina b2 de molecula pequena
HK1220136A1 (zh) 2013-03-14 2017-04-28 Shire Human Genetic Therapies, Inc. 治疗b2-缓激肽受体介导的血管性水肿的方法
EP3713928B1 (en) 2017-11-24 2022-01-12 Pharvaris Netherlands B.V. Novel bradykinin b2 receptor antagonists

Also Published As

Publication number Publication date
PL3713928T3 (pl) 2022-07-11
IL274883B2 (en) 2023-11-01
HUE058217T2 (hu) 2022-07-28
EA202091256A1 (ru) 2020-10-05
US11261173B2 (en) 2022-03-01
BR112020010298A2 (pt) 2020-11-17
AU2018371186B2 (en) 2022-05-12
KR20200094174A (ko) 2020-08-06
LT3713928T (lt) 2022-05-10
US20200255405A1 (en) 2020-08-13
TW202017916A (zh) 2020-05-16
SI3713928T1 (sl) 2022-09-30
HRP20220429T1 (hr) 2022-05-27
WO2019101906A1 (en) 2019-05-31
EP3998259A1 (en) 2022-05-18
ES2908409T3 (es) 2022-04-29
SMT202200154T1 (it) 2022-05-12
EP3713928A1 (en) 2020-09-30
MX2020005287A (es) 2020-08-13
RS63087B1 (sr) 2022-04-29
JP7164619B2 (ja) 2022-11-01
US10836748B2 (en) 2020-11-17
SG11202004653TA (en) 2020-06-29
NZ764304A (en) 2024-02-23
AU2018371186A1 (en) 2020-05-28
MA50804B1 (fr) 2022-05-31
UY37981A (es) 2019-06-28
PH12020550683A1 (en) 2021-03-15
AR113839A1 (es) 2020-06-17
IL274883B1 (en) 2023-07-01
MA50804A (fr) 2020-09-30
KR102413321B1 (ko) 2022-06-24
JP2023002701A (ja) 2023-01-10
DK3713928T3 (da) 2022-04-04
CA3082948A1 (en) 2019-05-31
US11820756B2 (en) 2023-11-21
JP2021504464A (ja) 2021-02-15
CN111433196B (zh) 2023-06-06
US20210017158A1 (en) 2021-01-21
US20220135543A1 (en) 2022-05-05
EP3713928B1 (en) 2022-01-12
TWI768156B (zh) 2022-06-21
IL274883A (en) 2020-07-30
CN111433196A (zh) 2020-07-17
CY1125348T1 (el) 2024-02-16

Similar Documents

Publication Publication Date Title
IL274883A (en) BRADYKININ B2 receptor antagonists
IL258892B (en) Calcitonin gene-related peptide receptor antagonists
EP3732163A4 (en) MUSCARIN M4 ACETYLCHOLIN RECEPTOR ANTAGONISTS
GB201702617D0 (en) Receptor
IL275084A (en) Triazolobenzazepines as vasopressin V1A receptor antagonists
IL258893A (en) Cgrp receptor antagonists
ZA201800452B (en) Cgrp receptor antagonists
EP3665175A4 (en) MUSCARIN M4 ACETYLCHOLIN RECEPTOR ANTAGONISTS
SG11202002207QA (en) Trpv2 antagonists
GB201815629D0 (en) Antagonists
IL258894A (en) Cgrp receptor antagonists
IL264537A (en) Cyclic peptides as c5 a receptor antagonists
GB201707499D0 (en) Orexin receptor antagonists
GB201702174D0 (en) Orexin receptor antagonists
SG11202105784WA (en) Antagonists
ZA201807767B (en) Angiotensin-1-receptor antagonists
GB201707504D0 (en) Orexin receptor antagonists
GB201701887D0 (en) Receptor
GB201700926D0 (en) Receptor
PT3464324T (pt) Antagonistas de recetores da angiotensina-1